<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM</span><br/>(lee'vo-nor-jes-trel)<br/><span class="topboxtradename">Mirena<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">progestin</span><br/><b>Prototype: </b>Norgestrel<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>52 mg unit</p>
<h1><a name="action">Actions</a></h1>
<p>A progestogen that induces morphological changes in the endometrium including glandular atrophy, a leukocytic infiltration,
         and decrease in glandular and stromal mitoses. Mechanisms of action not fully understood.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Contraceptive. May act by preventing follicular maturation and ovulation, thickening of the cervical mucus of the uterus,
         thus preventing passage of sperm into the uterus, or decreasing ability of sperm to survive in an environment of altered endometrium.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hormonal contraception.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component of the product; previously inserted IUD which has not been removed; pregnancy (category
         X), suspicion of pregnancy, within 6 wk of giving birth or prior to complete involution of the uterus; history of ectopic
         pregnancy or any condition which predisposes to ectopic pregnancy; history of uterine anomalies which distort the uterine
         cavity; acute PID or history of PID unless there has been a subsequent intrauterine pregnancy; cervicitis or vaginitis or
         other lower genital tract infection; genital actinomycosis; woman or partner has multiple sex partners; vaginal bleeding of
         unknown etiology; postpartum endometriosis or septic abortion in past 3 mo; abnormal Pap or suspected/known cervical neoplasm;
         known or suspected carcinoma of the breast; acute liver disease or liver tumor; immune deficiency states; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Women at risk for venereal disease; anemia; diabetes mellitus; history of psychic depression; persons susceptible to acute
         intermittent porphyria; fluid retention; history of migraines; impaired liver function; presence or history of salpingitis;
         venereal disease; genital bleeding of unknown etiology; previous pelvic surgery.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Contraception</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intrauterine</span> Insert device on 7<sup>th</sup> day of menstrual cycle, may leave in place up to 5 y<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intrauterine</span><br/><ul>
<li>Inserted only by physician or other person qualified by special training in the intrauterine system.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> Hypertension. <span class="typehead">GI:</span> Abdominal pain, nausea. <span class="typehead">Endocrine:</span> Breast tenderness/pain. <span class="typehead">Hematologic:</span> Anemia. <span class="typehead">Metabolic:</span> Weight gain. <span class="typehead">CNS:</span> Depression, emotional lability, headache (including migraine), nervousness. <span class="typehead">Skin:</span> Acne, alopecia, eczema. <span class="typehead">Urogenital:</span> Amenorrhea, dysmenorrhea, leukorrhea, decreased libido, vaginal moniliasis, vulvovaginal disorders, cervicitis, dyspareunia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span>  Few weeks. <span class="typehead">Duration:</span> 5 y. <span class="typehead">Distribution:</span> 86% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in both urine and feces. <span class="typehead">Half-Life:</span> 37 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for decreased pulse, perspiration, or pallor during insertion. Keep patient supine until these signs have disappeared.</li>
<li>Monitor BP especially with preexisting hypertension.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report S&amp;S of PID immediately: (e.g., prolonged or heavy bleeding, unusual vaginal discharge, abdominal or pelvic pain or
            tenderness, painful sexual intercourse, chills, fever, and flu-like symptoms).
         </li>
<li>Report any of the following to physician immediately: Migraine (if not experienced before) or exceptionally severe headache,
            or jaundice.
         </li>
<li>
            							Note: Diabetics should monitor closely blood glucose for indications of loss of control.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>